BARTH SYNDROME (BTHS) is an X-linked recessive condition caused by mutations in the tafazzin gene (TAZ) located on the distal portion of Xq28 (2) and is characterized by various forms of cardiomyopathy [dilated, left ventricular (LV) noncompaction, and occasionally hypertrophic], skeletal myopathy, recurrent neutropenia, growth deficiency, and urinary 3-methyl glutaconic aciduria (24) . The tafazzins are a family of proteins that share homology with acyltransferases, enzymes essential in phospholipid and cardiolipin biosynthesis and remodeling (32) . Cardiolipin is an important component of the mitochondrial membrane and is necessary for proper membrane stabilization as well as for the optimal functioning of processes such as apoptosis and respiratory chain function. TAZ mutations in BTHS result in abnormal cardiolipin remodeling, leading to mitochondrial structural (36) and respiratory chain abnormalities that are variable and not well characterized (43) . Cardiac and skeletal muscle have high levels of cardiolipin (21) and, therefore, are most affected in BTHS.
Abnormal cardiolipin remodeling results in an essential absence of cardiolipin, but the functional consequences of this as it relates to O 2 utilization and energy metabolism have not been elucidated in patients with BTHS. Clinically, exercise intolerance and fatigue are frequent complaints in BTHS; however, objective evidence for exercise intolerance and the degree of reduced functional capacity have not been previously evaluated. It is not known if exercise intolerance is related to impaired skeletal muscle O 2 extraction and utilization, reduced cardiac function, or global energy production deficits due to abnormal mitochondrial function in both tissues. Studies in non-BTHS-related mitochondrial myopathies have shown that, although cardiomyopathy may be part of the disease process, exercise intolerance is primarily mediated by a decreased ability of the skeletal muscle to extract and utilize O 2 from the blood during exercise (42) . We sought to determine if 1) abnormal mitochondrial function in BTHS leads to clinically significant abnormalities of skeletal muscle O 2 extraction/utilization and 2) exercise intolerance in BTHS is related to impaired O 2 extraction/utilization, impaired cardiac function, or both.
METHODS

Participants
We conducted an observational, cross-sectional study of 15 patients with BTHS and 9 healthy controls (all Caucasian) who were sedentary, which was defined as not actively participating in an organized sport or in routine exercise Ͼ1 time/wk (Table 1) . Control participants were a convenience sample of siblings, extended family, and friends of the BTHS participants. Participants were recruited during the 2008 Barth Syndrome International Scientific, Medical, and Family Conference held in Clearwater, FL. Any participant with a diagnosis of BTHS and a confirmed TAZ mutation was eligible for the study. Upon screening, all participants received a physical examination, including a medical history. Participants with BTHS also received fasting blood chemistry. Pro-brain natriuretic peptide was measured as a marker of LV dysfunction (33) . All laboratory analyses were performed at the University of Florida School of Medicine/Shands Medical Center clinical laboratory according to standard clinical practices.
Participants with BTHS were taking several cardiac medications among others at the time of testing (Table 1) . Informed written consent was obtained from all participants or the parents of the participants, verbal assent was obtained from all participants, and the study was approved the Human Research Protection Office of the University of Florida School of Medicine.
Exercise Protocol
After baseline echocardiography, each participant performed a graded exercise test on an electronically braked cycle ergometer (SensorMedics/VIASYS Healthcare, Yorba Linda, CA). The exercise test began by participants pedaling at a rate of 60 revolutions/min with no load for 1 min (warm up). After the warm-up period, the work rate (WR) on the cycle ergometer started at 10 W and increased 10 W/min for BTHS participants and started at 20 W and increased 20 W/min for control participants until volitional exhaustion. Twelve-lead ECG, blood pressure, O 2 consumption (V O2), CO2 production (V CO2), and ventilation (VMax, SensorMedics/VIASYS Healthcare) were continuously measured. After volitional exhaustion, participants were immediately placed in the supine position, where a postexercise ECG was performed within 15-30 s. Exercise tests were considered to be maximal if the peak heart rate (HR) was Ն85% of that predicted for age (220 Ϫ age) and/or the peak respiratory exchange ratio (RER; V CO2/V O2) was Ն1.15 (1). The predicted peak V O2 (V O2 peak) was determined using the equation of Cooper et al. (10) .
Cardiac Function Evaluation
Rest. All participants underwent echocardiography during quiet rest using a standardized protocol designed to evaluate LV size, morphology,and systolic and diastolic function. All ECGs were recorded digitally and in DVD format, and the results were interpreted and measured by the same cardiologist (C. T. Spencer), who was blinded to participant identification. Resting HR and blood pressure were recorded for each study participant. ECGs were obtained using Phillips 7500 echocardiography machines (Phillips Medical Systems, Bothell, WA). LV dimensions were measured from two-dimensional (2-D) parasternal short-axis images, and the LV mass, volume, and ejection fraction (EF) were obtained from apical and short-axis images and calculated using the 5/6 area-length method. Diastolic function was measured by pulsed-wave Doppler mitral inflow and myocardial velocities obtained by tissue Doppler imaging (TDI) in the apical four-chamber view at the LV lateral wall, septum, and right ventricular free wall.
Exercise. During exercise testing, participants were instructed to indicate to the testing personnel when peak exercise capacity was reached and volitional exhaustion was closely imminent. At peak exercise, participants were immediately transferred to an imaging table and placed in the left lateral decubitis position for echocardiography. 2-D apical and parasternal short-axis images were obtained for the evaluation of LV size and systolic function. Cardiac output was calculated from end-diastolic volume (EDV)/end-systolic volume, and HR was obtained from 2-D images during rest and at peak exercise.
Evaluation of Skeletal Muscle Tissue O 2 Extraction and Utilization Using Near-Infrared Spectroscopy.
The near-infared spectroscopy (NIRS) measurements used a continuous light source, four-wavelength (690, 780, 805, and 850 nm) spectrophotometer (FORE-SIGHT, CAS Medical Systems, Branford, CT). One sensor was placed over the belly of the vastus lateralis muscle midway between the lateral epicondyle and greater trochanter of the femur and secured by self-adherent wrap (Coban). The separation distance between the light sources and detector pairs was 4 cm. As stated above, participants cycled at 60 revolutions/min beginning at 10 W (BTHS) or 20 W (control) and then resistance increased every minute by 10 W for BTHS participants and 20 W for control participants until volitional exhaustion. The monitor was validated for the brain (27, 29) and skeletal muscle [data not published but Federal Drug Administration (FDA) approved, CAS Medical Systems] with FDA clearance for routine clinical use, demonstrating a precision of 5 Ϯ 1% (mean Ϯ SD). Changes of oxyhemoglobin (HbO 2), deoxyhemoglobin (deoxyHb), and total Hb were computed using a built-in algorithm developed at the University College of London (11, 31, 48) . The University College of London algorithm was modified for the different wavelengths used in FORE-SIGHT by assigning the respective absorption coefficients for HbO 2 and deoxyHb (31) . The differential path length factor was estimated to be 5.5 for limb skeletal muscle (13) and was assumed to be similar between groups and not change during exercise. For tissue O 2 saturation (StO 2 ) measurements, FORE-SIGHT used a proprietary differential wavelength algorithm, which compensates for variations in background tissue light absorption and scattering that could occur during exercise (4, 14) . The FORE-SIGHT St O 2 algorithm was validated against concurrent measurements of invasively drawn blood samples and was FDA approved.
Statistics
Statistical comparisons were performed using SAS version 9.1 (Cary, NC). Data are shown as means Ϯ SD in the text and tables and means Ϯ SE in the figures. Due to the age difference between BTHS and control participants, differences between groups for the continuous demographic, NIRS, and peak exercise variables were determined using analyses of covariance (ANCOVA) with age as the covariate. Medications n (%)
Values are means Ϯ SD; n, number of participants. BTHS, Barth syndrome; GCSF, granulocyte colony-stimulating factor. Other medications include losartan, riboflavin, Singulair, iron, thiamine, vitamin C, and bactrim. *P Ͻ 0.05. †All subjects with proven ventricular arrhythmia. NA, not available.
Repeated-measures ANCOVA (age, mixed model) was used to determine differences in cardiorespiratory and NIRS variables between groups at each WR during exercise. We also examined differences in variables in secondary analyses by grouping BTHS participants who were and were not taking ␤-blocker medications and by New York Heart Association functional class compared with control participants (ANCOVA). Pearson correlation coefficients (r) were used to determine if relationships existed between continuous variables. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Demographics
Participants with BTHS were slightly older than control participants but were similar in height, weight, and body mass index (Table 1) . At the time of the study, approximately half of the BTHS participants were taking ␤-blockers and three-quarters were taking angiotensin-converting enzyme inhibitor therapy (Table 1 ). In addition, approximately half of the participants with BTHS were taking digoxin, 40% were taking granulocyte colony-stimulating factor (GCSF), and 20% were taking coenzyme Q and carnitine (Table 1) . Control participants were not taking any medications at the time of the study that would influence exercise capacity.
Cardiorespiratory Variables
V O 2 peak expressed in absolute (l/min) or relative (ml·kg Ϫ1 ·min Ϫ1 ) terms was significantly lower in BTHS compared with control participants (Table 2 and Fig. 1A ). According to criteria outlined by Cooper et al. (10) , participants with BTHS only achieved 36% of the predicted V O 2 peak compared with control participants, who achieved 83% of the predicted V O 2 peak . Peak WR was also significantly lower in BTHS than control participants ( Table 2 ). The total increase in HR from rest to peak exercise was significantly blunted in participants with BTHS (BTHS: 57 Ϯ 40 beats/min vs. control: 92 Ϯ 19 beats/min, P Ͻ 0.001) as was peak HR (Table 2 and Fig. 1B ), but HR was exaggerated during lower WR levels in BTHS compared with control participants (Fig. 1B) . Peak RER (expired V CO 2 /V O 2 ) was significantly higher in BTHS than control participants (Table 2 and Fig. 2 ) and well exceeded the criterion for a maximal exercise effort (1) in both groups, indicating that a less than maximal effort was not the limiting factor in exercise intolerance in BTHS participants. In addition, RER was significantly higher in BTHS versus control participants at low levels of exercise intensity (Fig. 2) , indicating anaerobic energy supplementation at very low workloads. Ventilatory threshold, calculated by the V-slope method (3), was significantly lower in participants with BTHS than control participants but occurred at a similar percentage of V O 2 peak in both groups ( Table 2 ). The ventilation-V CO 2 slope was significantly higher in BTHS participants at the ventilatory threshold and tended (P Ͻ 0.11) to be higher at peak exercise in BTHS than control participants (Table 2) . Values are means Ϯ SD; n ϭ 9 control participants and 15 BTHS participants. All analyses were corrected for age (by analysis of covariance). HR, heart rate; V O2, O2 consumption. The percent of perdicted V O2 was reached as per Cooper et al. (10) 
Echocardiography
Rest. At rest, there were no differences in HR between participants with BTHS and control participants (Table 3) . LV mass and EDV were similar between groups. EF and LV ejection time at rest were lower in BTHS than control participants, although the mean EF in the BTHS cohort was only mildly depressed (EF range: 36 -58%), and the mean LVEDV was within normal limits (Table 3) . Septal peak systolic and early diastolic velocities measured by TDI during rest were significantly lower in BTHS than control participants, indicating that both systolic and diastolic function in BTHS participants was decreased compared with control participants (Table 3) .
Exercise. EF during peak exercise was significantly lower in BTHS compared with control participants, and the absolute change and percent change in EF from baseline to peak exercise was significantly blunted in BTHS compared with control participants (Table 3 and Fig. 3) .
Effect of ␤-Blocker Therapy
Approximately half of the BTHS participants were taking ␤-blocker therapy, and, due to the potential blunting effect of ␤-blocker medications on HR and contractility, especially during exercise, we also compared variables at peak exercise in BTHS participants taking ␤-blockers (BTHS/␤-blocker) versus not taking ␤-blockers (BTHS/no ␤-blocker) and in control participants. , P Ͻ 0.001) and peak WR (data not shown) were similar between BTHS/␤-blocker and BTHS/no ␤-blocker participants but significantly lower compared with control participants. EF at peak exercise was significantly lower in BTHS/␤-blocker than BTHS/no ␤-blocker participants, but both BTHS groups were significantly lower than the control group (Fig. 3) . Peak HR tended (P ϭ 0.11) to be lower in BTHS/␤-blocker than BTHS/no ␤-blocker participants and was significantly lower (P Ͻ 0.05) than control participants (BTHS/␤-blocker: 135 Ϯ 24 beats/min vs. BTHS/no ␤-blocker: 156 Ϯ 13 beats/min vs. control: 165 Ϯ 18 beats/min, P ϭ 0.11); however, there was no difference between BTHS/no ␤-blocker and control participants. These results suggested that ␤-blocker therapy influenced cardiac reserve in part during exercise through reductions in HR at peak exercise but ultimately did not appear to affect V O 2 peak . Fig. 3 . Ejection fraction (%) at baseline and at peak exercise in BTHS participants taking and not taking ␤-blocker medication and in Cntl participants. Pre, before exercise; Post, after exercise. *P Ͻ 0.05 vs. baseline; $P Ͻ 0.05 vs. both BTHS groups. Values are means Ϯ SD; n ϭ 9 control participants and 15 BTHS participants. All analyses were corrected for age (by analysis of covariance). LV, left ventricular; LVM, LV mass; EDV, end-diastolic volume; ESV, end-systolic volume; E, early diastolic filling velocity; A, late diastolic filling velocity; E=, velocity during early diastole measured at the septum; EF, ejection fraction; S=, myocardial velocity during systole measured at the septum. *P Ͻ 0.01; †P Ͻ 0.05.
Effect of Functional Class
Upon examination, there were no differences in V O 2 , HR, or EF at peak exercise between different New York Heart Association functional classes within the BTHS participants, and BTHS participants as a group followed a similar pattern compared with control participants as above. Figure 4 shows the changes of NIRS parameters deoxyHb, HbO 2 , and total Hb measured in skeletal muscle (in M) and St O 2 (in %) for control and BTHS participants during the exercise protocol. For the control group, as WR increased with time, although not statistically significant from BTHS participants at WRs of 10 -60 W, deoxyHb increased linearly with exercise intensity, indicating increased skeletal muscle O 2 extraction with increasing exercise intensity (Fig. 4B) . DeoxyHb in BTHS participants did not change and even slightly decreased during exercise, suggesting impaired O 2 extraction (Fig. 4B) . Mean HbO 2 decreased in control participants but to a lesser extent compared with the change in deoxyHb, suggesting that HbO 2 may have been affected by arteriolar vasodilation during exercise, leading to increased blood flow secondary to the decrease of HbO 2 due to O 2 extraction (Fig. 4A) . HbO 2 paradoxically increased in BTHS participants and was significantly different than control participants at WRs of 40 -60 W (Fig. 4A) . This increase during exercise may be due arteriolar vasodilation leading to increased blood flow but without the decrease of HbO 2 due to O 2 extraction as that of the control response. Mean total Hb, the sum of deoxyHb and HbO 2 , increased in both groups (after 30 W in control participants) during exercise and was significantly greater in BTHS participants at the 60-W WR (Fig. 4C ).
NIRS
In the control group, skeletal muscle St O 2 decreased as a function of WR during exercise, further supporting the notion of increased O 2 extraction during exercise in control participants (Fig. 4D) . Skeletal muscle St O 2 dropped from a mean baseline value of 60.2 Ϯ 7.6% to 45.8 Ϯ 8.9% during peak exercise (at exhaustion) and then at 3 min postexercise climbed to 79.5 Ϯ 1.4% due to the hyperemic response (not shown). For the BTHS group, skeletal muscle St O 2 increased as a function of WR during exercise, opposite of the control response. Skeletal muscle St O 2 increased in BTHS participants from a baseline value of 58.4 Ϯ 8.4% to 68.9 Ϯ 7.0% during peak exercise (at exhaustion) and then at 3 min postexercise climbed to 73.1 Ϯ 5.1%. Baseline (preexercise) values of skeletal muscle St O 2 were not significantly different between control and BTHS participants but were significantly different (P Ͻ 0.001) during peak exercise.
Overall, NIRS muscle O 2 extraction indicators of St O 2 changes from rest to peak exercise were paradoxically opposite (BTHS: 8 Ϯ 16 vs. control: Ϫ15 Ϯ 9, P Ͻ 0.01), and deoxyHb change was blunted (BTHS: 0 Ϯ 12 vs. control: 10 Ϯ 8, P Ͻ 0.09) in BTHS compared with control participants.
Correlation Analyses
Age was significantly related to V O 2 peak expressed per body weight (r ϭ Ϫ0.46, P Ͻ 0.02) but not when expressed in absolute terms (i.e., l/min). The body mass index was significantly correlated with V O 2 peak (in l/min, r ϭ 0.52, P Ͻ 0.009) and peak WR (r ϭ 0.60, P Ͻ 0.003). A higher resting EF was associated with higher V O 2 peak (in l/min: r ϭ 0.52, P Ͻ 0.01; and in ml·kg Ϫ1 ·min Ϫ1 : r ϭ 0.59, P Ͻ 0.01) and peak WR (r ϭ 0.54, P Ͻ 0.008). Lower diastolic function at rest (septal wall velocity measured by TDI) was significantly related to lower peak lower V O 2 peak (in l/min: r ϭ 0.57, P Ͻ 0.005; and in 
ml·kg
Ϫ1 ·min Ϫ1 : r ϭ 0.62, P Ͻ 0.002) and peak WR (r ϭ 0.53, P Ͻ 0.01). A lower EF at peak exercise was significantly related to lower V O 2 peak (in l/min: r ϭ 0.76, P Ͻ 0.001; and in ml·kg Ϫ1 ·min Ϫ1 : r ϭ 0.81, P Ͻ 0.001) and peak WR (r ϭ 0.76, P Ͻ 0.001). In addition, a blunted response in EF from baseline to peak exercise was significantly related to lower V O 2 peak (in l/min: r ϭ 0.67, P Ͻ 0.001; and in ml·kg Ϫ1 ·min Ϫ1 : r ϭ 0.76, P Ͻ 0.001) and peak WR (r ϭ 0.62, P Ͻ 0.001). Interestingly, HRs at peak exercise were not significantly related to V O 2 peak but were related to peak WR (r ϭ 0.46, P Ͻ 0.03). In contrast, the slope of deoxyHb (an index of muscle O2 extraction) from rest to peak exercise was related to V O 2 peak (in l/min: data not shown; and in ml·kg Ϫ1 ·min Ϫ1 : r ϭ 0.61, P Ͻ 0.01).
DISCUSSION
This study provides the first objective evidence for marked exercise intolerance in boys and young men with BTHS. Importantly, this study also provides the first data demonstrating that the pathophysiological effect of abnormal cardiolipin remodeling of the mitochondria results exercise intolerance that is mediated by both diminished skeletal muscle O 2 extraction/utilization and impaired cardiac contractile reserve in BTHS participants regardless of the presence of ␤-blocker medication or functional classification.
During graded exercise in healthy individuals, the near linear rise in V O 2 is accounted for by nearly linear rises in HR and skeletal muscle O 2 extraction/utilization (35) , as seen in the healthy control participants in the present study. Although a normal response in submaximal V O 2 occurred in individuals with BTHS, the impairment in V O 2 peak during graded exercise appeared to be mediated in part due to blunted peripheral muscle O 2 extraction/utilization. The HR response to graded exercise was exaggerated in BTHS participants at each WR (i.e., suggesting adequate or compensatory blood flow) except at peak exercise, where it was blunted compared with control participants; this response is typically seen in other mitochondrial myopathies (18, 41, 42) . Although ventilation-V CO 2 at the ventilatory threshold was significantly greater in BTHS than control participants and tended to be greater at peak exercise, ventilation-V CO 2 was not at the high levels frequently seen in those with advanced heart failure, which typically indicate a failure of an increase in stroke volume during exercise (30) . However, the contractile reserve, as determined by changes in EF from rest to peak exercise, was limited in BTHS participants and that, in addition to skeletal muscle O 2 metabolism impairments, reduced cardiac function during exercise also contributes to exercise intolerance, regardless of increases in HR. In addition, we also found significantly lower cardiac output at peak exercise by 2-D echocardiography (data not shown); however, measurement of cardiac output during exercise with 2-D echocardiography can significantly underestimate stroke volume by as much as 60% (8), and thus we are not fully confident these values are precise. Clearly, the negative HR and contractility influences of ␤-blocker therapy cannot be understated; however, even those participants with BTHS who were not on ␤-blocker therapy exhibited an impaired contractility response to exercise, indicating that having BTHS in the absence of ␤-blocker therapy contributed to exercise intolerance. Nonetheless, strong relationships between both the response in EF to exercise and the slope of deoxyHb during exercise with V O 2 peak and peak WR provide additional support to the notion that the combination of cardiac and skeletal muscle impairment mediates exercise intolerance in BTHS.
Exercise intolerance in BTHS appears to share similar characteristics with mitochondrial myopathies and adult heart failure. V O 2 peak values in BTHS participants in the present study are consistent with values reported in adults with class B heart failure (45) and those reported in various inherited mitochondrial myopathies (42) . The primary known mechanism of BTHS is a TAZ mutation that leads to abnormal cardiolipin remodeling, impairing both the inner (6) and outer (16) layers of the mitochondrial membrane. Evidence in nonhuman BTHS models supports the notion of TAZ mutation-mediated mitochondrial dysfunction (2, 9, 28) . Cardiolipin, a phospholipid, is a major constituent in several respiratory chain and carrier proteins of the mitochondria (37) . Therefore, it is not surprising that in humans with BTHS, we were able to demonstrate skeletal muscle O 2 extraction impairments during exercise (suggestive of mitochondrial impairment) with NIRS. Indeed, skeletal muscle O 2 extraction during exercise measured by NIRS is also reduced in non-BTHS mitochondrial myopathies (7, 18) , and only one other study (18) has used NIRS to identify this. However, in contrast to BTHS, cardiac output during exercise appears to be less affected in other mitochondrial myopathies (41) .
Skeletal muscle anaerobic metabolism in participants with BTHS appeared to occur earlier during exercise as the peak RER well exceeded (ϳ1.5) the accepted level to be considered peak exercise [1.15 (1)], suggesting an increased reliance on glycolytic metabolism during exercise leading to premature fatigue and exhaustion. An increase in RER during exercise is thought to represent H ϩ buffering in the blood by bicarbonate in response to skeletal muscle lactate production and release from intense exercise (35) as well as hyperventilation at the respiratory compensation point aimed at reducing arterial PCO 2 to correct metabolic acidosis (44) . Although a higher than normal RER at peak exercise has been reported in non-BTHS mitochondrial myopathies, the present values in BTHS participants exceed values seen in other mitochondrial myopathies (42) . This may indicate more severe lactic acidemia in BTHS than other mitochondrial myopathies with exercise; however, we did not measure serum lactate levels in the present study. Unpublished data from one BTHS patient (22 yr old; not included in this study) during a separate clinical exercise study may provide support for this notion as the serum lactate level at peak exercise was 7 mmol/l, a level higher than that reported in some studies of mitochondrial myopathies at peak exercise (ϳ4.5 mmol/l) (12, 39) but not all (18) . These data, in combination with the finding of significantly lower ventilatory threshold in BTHS participants in the present study, suggest severe mitochondrial skeletal myopathy in individuals with BTHS.
Limitations
There were several potential limitations of the study. Participants with BTHS were significantly older than controls; however, all analyses were performed adjusting for age. We also recognize that although the control participants were considered sedentary, they were likely more active than BTHS participants due the inherent exercise intolerance and reported fatigue in BTHS participants. As previously stated, cardiac output was measured by 2-D echocardiography rather than Doppler echocardiography, likely resulting in an underestimation of cardiac output during exercise, as a previous study (8) has shown a 60% underestimation of cardiac output during exercise using 2-D echocardiography. We believe that the data are still useful as identical techniques were used to compare BTHS and control participants, thus distributing the error throughout both groups. In addition, cardiac output was measured immediately postexercise; however, HR dropped 9.8% in BTHS participants and 13% in control participants from peak exercise HR to the HR measured during the ECG subsequently slightly underestimating peak cardiac output. In addition, using cycle ergometry rather than using a treadmill for peak exercise testing may have underestimated V O 2 peak both groups (20, 47) , especially in BTHS participants by potentially highlighting the peripheral muscle fatigue in BTHS participants.
We recognize that the absence of blood lactate concentrations to support our findings of impaired muscle O 2 extraction and high RER values at peak exercise in BTHS participants is a limitation of the study. Due to the invasive nature of collecting blood lactate concentrations and the difficulty performing this procedure in children and in a conference setting, we were unable to measure blood lactate concentrations in the participants.
During the time of exercise testing, several participants with BTHS were taking medications that could have influenced, albeit positively, exercise tolerance and the components thereof. Approximately 40% of the participants were taking GCSF during the time of exercise testing. GCSF has been shown to improve exercise tolerance (6-min walk time) in patients with heart failure (22) ; however, all studies examining the effect of GCSF on exercise tolerance are not equivocal (46) . Also, coenzyme Q has been shown to improve exercise capacity in both mice (15) and humans with mitochondrial disease (17) . In addition, carnitine has been shown to improve exercise tolerance in mice (5, 38) . Taken together, these medications may have influenced the data by blunting an even greater impairment in exercise tolerance in BTHS participants.
The clinical ramifications of our findings are important. The extremely low functional capacity in this patient group should not be interpreted as simply a reflection of cardiac performance but rather in the context of their limited O 2 extraction as well. In addition, the finding of low ventilatory threshold that occurs during an energy requirement associated with light to moderate employment and recreational activities (1) suggests that these individuals experience fatigue in many everyday activities. Moreover, the finding of an unusually high RER at peak exercise may suggest that individuals with BTHS may experience frequent lactic acidemia with strenuous exercise; however, exercise studies measuring serum lactate are needed to confirm this. Finally, the establishment of exercise intolerance in BTHS participants poses the question of whether individuals with BTHS can safely and effectively participate in exercise training. Evidence from non-BTHS heart failure demonstrates that chronic exercise training improves exercise tolerance (26), skeletal muscle oxidative metabolism (19) , chronotropic incompetence (25) , and quality of life (34) . Moreover, chronic exercise training in non-BTHS mitochondrial myopathies is safe and improves exercise tolerance (23) , reduces serum lactate level during exercise (39, 40) , and improves skeletal muscle oxidative metabolism (40) , suggesting that individuals with BTHS may indeed benefit from exercise training; however, this area warrants further investigation.
Conclusions
In summary, we have found that severe exercise intolerance in BTHS participants is due to a combination of skeletal muscle impairments and decreased cardiac reserve, which is consistent with cardiac and skeletal mitochondrial myopathy. These findings provide further insight into the pathophysiology of BTHS that complements basic investigations into the results of TAZ deficiency. These data indicate that limited O 2 uptake/ utilization, presumably due to impaired mitochondrial function from abnormal cardiolipin, directly contribute to the severely decreased functional capacity. Additionally, individuals with BTHS should receive workplace and educational considerations due to evidence of fatigue and activity intolerance during moderate-intensity routine activities of daily living. Finally, these finding suggest that additional studies examining the safety and efficacy of chronic aerobic exercise training in BTHS participants are warranted.
